Orthobiologics Market Analysis, Size, Trends | Australia | 2020-2026 | Medsuite
- Year: 2020
- Scope: 2016-2026
- Region: Australia
- Pages: 285
- Published Date: 07/02/2020
- Type: MedSuite
By 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026.
Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.
While this MedSuite report contains all of the Australian Orthopedic Biomaterials market data and analysis, each of the market segments is also available as stand-alone MedCore reports. This allows you to get access to only the market research that you need.
DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2026, and Historical Data to 2016
- Market Drivers & Limiters for Each Orthopedic Biomaterials Device market
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Orthobiologics Procedure Volumes
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- Related Press Releases from Top Competitors
Market Value and Industry Trends
With some exceptions, tissue supply for allografts and DBM allografts is constrained by the number of available donors. Furthermore, allografts are primarily sold by bone banks in Australia, which is attributed to a relatively high barrier to entry to the market for international companies. As the population ages, there will be a lower supply of eligible bone graft donors.
Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, over 15% of Australians were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.
Single-injection HA viscosupplementation products are relatively new to the Australian market. In 2019, there were three single-injection products available: Sanofi’s Synvisc-One®, Bioventus’ Durolane® and Anika Therapeutics’ MONOVISC®. Although three-injection products were available in Australia before single-injection products, the benefits of the latter are typically perceived to outweigh the favorable cost of the former. As a result, single-injection products are expected to> continue to cannibalize three-injection products over the forecast period.
By 2020, the leading competitor in the Australian orthopedic biomaterials market was Medtronic. The company has established this role through strong performance of its growth factor product line, INFUSE®, which first entered the market in 2006. Medtronic also held a notable position in the DBM allograft and synthetic markets.
DePuy Synthes was the second-leading competitor in the Australian market, which was solely attributed to its leading position in the orthopedic bone graft substitute market. The company was particularly strong in the DBM allograft market, which continues to be the fastest-growing bone graft substitute segment.
Other notable competitors included, but were not limited to, Stryker, bone banks, Wright Medical, Cerapedics, Sanofi, Bioventus and Anika Therapeutics. Unlike the bone graft substitute market, which is heavily fragmented, the orthopedic graft factor and HA viscosupplementation markets are controlled by a smaller number of companies.
Click on each title to view more detailed market segmentation.
- Procedure Volumes for Orthopedic Biomaterials Devices – MedPro – The Complete procedural analysis for each segment of the Australian Orthopedic Biomaterials market.
- Orthopedic Bone Graft Substitute Market – MedCore – This market is further segmented by Material Type, including Allograft, Demineralized Bone Matrix Allograft, and Synthetic. Each of these Material Types are segmented by Spine, Trauma, Large Joint Reconstruction, Craniomaxillofacial, and Oncology.
- Orthopedic Growth Factor Market – MedCore – In-depth analysis of the Orthopedic Growth Factor market.
- Hyaluronic Acid Viscosupplementation Market – MedCore – This market is categorized by Treatment Type, including Single-Injection and Three-Injection.
Detailed Market Segmentation
DON’T SEE THE SEGMENT OR DATA YOU NEED?
Feel free to contact us or send a request by pressing one of the buttons below.
TABLE OF CONTENTS FOR THE AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET REPORT SUITETABLE OF CONTENTS ILIST OF FIGURES VIIILIST OF CHARTS XVEXECUTIVE SUMMARY 1AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1COMPETITIVE ANALYSIS 3MARKET TRENDS 5MARKET DEVELOPMENTS 6PROCEDURE NUMBERS 7MARKETS INCLUDED 8KEY REPORT UPDATES 10VERSION HISTORY 10RESEARCH METHODOLOGY 11Step 1: Project Initiation & Team Selection 11Step 2: Prepare Data Systems and Perform Secondary Research 14Step 3: Preparation for Interviews & Questionnaire Design 16Step 4: Performing Primary Research 17Step 5: Research Analysis: Establishing Baseline Estimates 19Step 6: Market Forecast and Analysis 20Step 7: Identify Strategic Opportunities 22Step 8: Final Review and Market Release 23Step 9: Customer Feedback and Market Monitoring 24
PRODUCT ASSESSMENT2.1 INTRODUCTION 252.2 PRODUCT PORTFOLIOS 252.2.1 Bone Graft Substitutes 262.2.2 Growth Factors 3220.127.116.11 Other products 352.2.3 Hyaluronic Acid Viscosupplementation (HAV) 372.3 REGULATORY ISSUES AND RECALLS 402.3.1 Bone Graft Substitutes 402.3.1.1 Allografts 402.3.1.1.1 MTF 402.3.1.2 DBM 402.3.1.2.1 AlloSource 402.3.1.2.2 SeaSpine 418.104.22.168.3 RTI Surgical 422.214.171.124 Synthetics 4126.96.36.199.1 Abyrx 4188.8.131.52.2 Zimmer Biomet 422.3.2 Growth Factors 4184.108.40.206.1 Medtronic 422.3.3 Hyaluronic Acid Viscosupplementation 4220.127.116.11 Three-injection 418.104.22.168.1 Ferring Pharmaceuticals 432.4 CLINICAL TRIALS 442.4.1 Bone Graft Substitutes 422.214.171.124 Allografts 4126.96.36.199.1 Providence Medical Technology 4188.8.131.52.2 The University of Texas Health Science 4184.108.40.206.3 University of Winchester 4220.127.116.11 BDM 418.104.22.168.1 K2M 422.214.171.124.2 Zimmer Biomet 4126.96.36.199 Synthetics 4188.8.131.52.1 Baxter 4184.108.40.206.2 Bonesupport 4220.127.116.11.3 DePuy Synthes 418.104.22.168.4 NuVasive 422.214.171.124.5 RTI surgical 4126.96.36.199.6 Sunstar GUIDOR 502.4.1.4 Other materials and comparison 5188.8.131.52.1 Seoul National University Hospital. 5184.108.40.206.2 Sewon Cellontech 5220.127.116.11.3 SurgaColl Technologies Limited 518.104.22.168.4 University of Colorado 522.214.171.124.5 University of Padova 532.4.2 Growth Factors 5126.96.36.199.1 Bioventus 5188.8.131.52.2 Cerapedics 5184.108.40.206.3 CGBio 5220.127.116.11.4 Isto 518.104.22.168.5 Medtronic 522.214.171.124.6 NuVasive 5126.96.36.199.7 Wright 5188.8.131.52.8 Others 582.4.3 Hyaluronic Acid Viscosupplementation 5184.108.40.206.1 Anika Therapeutics 5220.127.116.11.2 Bioventus 602.4.3.1.3 Cario University 618.104.22.168.4 Ferring Pharmaceuticals 622.214.171.124.5 Federal University of Minas Gerais 6126.96.36.199.6 Fidia Pharma USA Inc. 6188.8.131.52.7 Istituto Ortopedico Rizzoli 6184.108.40.206.8 University Hospital 6220.127.116.11.9 Universidade Nova de Lisboa 64
AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW3.1 INTRODUCTION 653.1.1 Bone Graft Substitutes 653.1.2 Growth Factors 653.1.3 Hyaluronic Acid (HA) Viscosupplementation 663.2 CURRENCY EXCHANGE RATE 673.3 MARKET OVERVIEW AND TREND ANALYSIS 683.4 DRIVERS AND LIMITERS 763.4.1 Market Drivers 763.4.2 Market Limiters 763.5 COMPETITIVE MARKET SHARE ANALYSIS 783.6 MERGERS AND ACQUISITIONS 843.7 COMPANY PROFILES 863.7.1 Anika Therapeutics 863.7.2 Bioventus 873.7.3 DePuy Synthes 883.7.4 Ferring Pharmaceuticals 893.7.5 Fidia Pharmaceuticals 903.7.6 Genzyme (Sanofi Group) 913.7.7 Harvest Technologies (Terumo BCT) 923.7.8 Integra LifeSciences 933.7.9 Medtronic 943.7.10 Musculoskeletal Transplant Foundation (MTF) 963.7.11 NuVasive 973.7.12 Orthofix 983.7.13 RTI Surgical 993.7.14 Stryker 1003.7.15 Vericel Corporation (formerly Aastrom Bioscience) 1013.7.16 Zimmer Biomet 1023.8 SWOT ANALYSIS 1043.8.1 Anika Therapeutics 1043.8.2 Bioventus 1063.8.3 DePuy Synthes 1083.8.4 Ferring Pharmaceuticals 1093.8.5 Fidia Pharmaceuticals 1103.8.7 Harvest Technologies (Terumo BCT) 1123.8.8 Integra LifeSciences 1133.8.9 Medtronic 1143.8.10 Musculoskeletal Transplant Foundation (MTF) 1153.8.11 NuVasive 1163.8.12 Orthofix 1173.8.14 Stryker 1193.8.15 Vericel Corporation (formerly Aastrom Bioscience) 1203.8.16 Zimmer Biomet 121
PROCEDURE NUMBERS4.1 INTRODUCTION 1234.2 PROCEDURES 1244.2.1 Orthopedic Biomaterial Procedures by Segment 1244.2.2 Orthopedic Bone Grafting Procedures 1218.104.22.168 Units per Procedure by Indication 1222.214.171.124 Orthopedic Bone Grafting Procedures by Material 12126.96.36.199.1 Autograft Procedures by Indication 12188.8.131.52.2 Allograft Procedures by Indication 13184.108.40.206.3 DBM Allograft Procedures by Indication 13220.127.116.11.4 Synthetic Procedures by Indication 1318.104.22.168 Orthopedic Bone Grafting Procedures by Indication 1414.2.3 Orthopedic Growth Factor Procedures 1444.2.4 Hyaluronic Acid Supplementation Procedures 1422.214.171.124 Hyaluronic Acid Supplementation Procedures by Injection Cycle 146
ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET5.1 INTRODUCTION 1485.2 MARKET OVERVIEW 1495.2.1 Orthopedic Bone Graft Substitute Market by Material 1495.2.2 Orthopedic Bone Graft Substitute Market by Indication 1545.3 MARKET ANALYSIS AND FORECAST 1605.3.1 Total Orthopedic Bone Graft Substitute Market 1605.3.2 Orthopedic Bone Graft Substitute Market by Material 16126.96.36.199 Allograft Bone Graft Substitute Market 16188.8.131.52.1 Allograft Bone Graft Substitute Market by Indication 16184.108.40.206 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 17220.127.116.11.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication 1805.3.2.3 Synthetic Bone Graft Substitute Market 1918.104.22.168.1 Synthetic Bone Graft Substitute Market by Indication 1965.3.3 Orthopedic Bone Graft Substitute Market by Indication 222.214.171.124 Spine Bone Graft Substitute Market 2126.96.36.199 Cervical Spine Bone Graft Substitute Market 2188.8.131.52 Thoracolumbar Spine Bone Graft Substitute Market 2184.108.40.206 Trauma Bone Graft Substitute Market 2220.127.116.11 Non-Union Trauma Bone Graft Substitute Market 218.104.22.168 Fresh Fracture Trauma Bone Graft Substitute Market 222.214.171.124 Large Joint Reconstruction Bone Graft Substitute Market 2126.96.36.199 Hip Reconstruction Bone Graft Substitute Market 2245.3.3.9 Knee Reconstruction Bone Graft Substitute Market 22188.8.131.52 Foot Reconstruction Bone Graft Substitute Market 22184.108.40.206 Craniomaxillofacial Bone Graft Substitute Market 2305.3.3.12 Oncology Bone Graft Substitute Market 2325.4 DRIVERS AND LIMITERS 2345.4.1 Market Drivers 2345.4.2 Market Limiters 2345.5 COMPETITIVE MARKET SHARE ANALYSIS 236
ORTHOPEDIC GROWTH FACTOR MARKET6.1 INTRODUCTION 2406.1.1 BMP-2 (Medtronic) 2416.1.2 PDGF-BB (Wright Medical) 2416.1.3 P-15 Synthetic Small Peptide (Cerapedics) 2416.1.4 P-15 Synthetic Small Peptide (Biocomposites) 2416.2 MARKET ANALYSIS AND FORECAST 2426.3 DRIVERS AND LIMITERS 2446.3.1 Market Drivers 2446.3.2 Market Limiters 2446.4 COMPETITIVE MARKET SHARE ANALYSIS 246
HYALURONIC ACID VISCOSUPPLEMENTATION MARKET7.1 INTRODUCTION 2497.1.1 Benefits of Viscosupplementation 2507.1.2 Synovial Fluid 2507.2 MARKET OVERVIEW 2517.3 MARKET ANALYSIS AND FORECAST 2577.3.1 Total Hyaluronic Acid Viscosupplementation Market 2577.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 2597.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market 2617.4 DRIVERS AND LIMITERS 2637.4.1 Market Drivers 2637.4.2 Market Limiters 2637.5 COMPETITIVE MARKET SHARE ANALYSIS 265
iData’s 9-Step Research MethodologyOur reports follow an in-depth 9-step methodology which focuses on the following research systems:
- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.